Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
Biotechnology word cloud

SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks

The firms we cover on Wall Street are sometimes like covering the major sports teams. Analysts are like the top players and tend to move around as their career strengths ...
Read Full Story »
biotech

Credit Suisse Positive on Some Biotechs, Very Cautious on Others

Credit Suisse has launched new biotech coverage on Wednesday with two analysts at the firm. The biotech sector has been a wealth-creation engine in recent years. What is interesting here ...
Read Full Story »
biotech

Rising Short Interest in Biotech Stocks

The short interest data is out for the August 15 settlement date. Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts, ...
Read Full Story »
Biotechnology word cloud

Top Biotech Earnings Previews for the Week Ahead

Earnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will ...
Read Full Story »
research

Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings

For the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street has loudly stepped up to the plate and advised investors ...
Read Full Story »
Biotechnology word cloud

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

After the biotech stocks were absolutely crushed in the late winter and early spring, many of the top firms we cover on Wall Street were aggressive in their calls to ...
Read Full Story »
biotech

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

Over the years biotech investors who have owned the right stocks have made some very big money on Federal Drug Administration (FDA) approval of leading drug candidates. Typically biotech firms ...
Read Full Story »
biotech

Short Sellers Remain Vigilant Against Top Biotech Stocks

Short sellers have many reasons to bet against a stock, some of which are hedging or part of a larger theme. Other reasons may be a bet against a company ...
Read Full Story »
biotech

Top Biotech Stocks to Buy According to Portfolio Managers

After seeing three years of incredible outperformance, biotech investors had a pretty large comeuppance starting in late February that lasted almost two months. A new research report from Cowen suggests ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
West side view of the United States Capitol building.

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress over drug pricing concerns hit the ...
Read Full Story »
Wall St Bull statue

Oppenheimer Top Stocks to Buy as Bull Market Turns Five Years Old

Five years ago, many investors had thrown in the towel. The S&P 500 hit an ominous intraday low of 666 and closed at 676.53. The world was coming to an ...
Read Full Story »
Biotechnology word cloud

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across ...
Read Full Story »
Pills

UBS Has Nine Biotech Buyout and Merger Candidates

After three years of solid outperformance, most firms on Wall Street that we cover remain very positive on biotechnology as a whole. The analysts at UBS are not only bullish ...
Read Full Story »